Dyne Therapeutics, Inc.
Developing TfR1-targeted oligonucleotide conjugates for serious muscle diseases. Zeleciment rostudirsen is in the Phase 3 FORZETTO trial, with a U.S. accelerated-approval BLA planned.
Rare neuromuscular disease · Targeted oligonucleotide conjugates · Phase 3 / BLA planned